Focus: Tango Therapeutics is an oncology-focused biotech company developing novel cancer immunotherapies and targeted agents. The company operates as a clinical-stage biotech with a diversified pipeline across multiple tumor types.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Growing — net +5 jobs in 30d
13 jobs added vs 8 removed. Steady team buildout.
Suitable for early-career scientists and clinical professionals seeking high-impact oncology research roles, but carry-over risk if funding or clinical readouts disappoint.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Tango Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Tango Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Tango Therapeutics (TNGX) director receives RSU and option grants as board compensation - Stock Titan
Tango Therapeutics (TNGX) director receives RSU and option grants as board compensation Stock Titan
TNGX (NASDAQ: TNGX) affiliate files to sell 65,460 shares after option exercise - Stock Titan
TNGX (NASDAQ: TNGX) affiliate files to sell 65,460 shares after option exercise Stock Titan
Why This CEO Is Confident He Can Build On 'Unprecedented' Cancer News - Investor's Business Daily
Why This CEO Is Confident He Can Build On 'Unprecedented' Cancer News Investor's Business Daily
How New C-Suite Hires At Tango Therapeutics (TNGX) Have Changed Its Investment Story - simplywall.st
How New C-Suite Hires At Tango Therapeutics (TNGX) Have Changed Its Investment Story simplywall.st
Stifel raises Tango Therapeutics stock price target on drug combo potential - Investing.com
Stifel raises Tango Therapeutics stock price target on drug combo potential Investing.com
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Moderate Buy" by Brokerages MarketBeat
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles